The Association of the British Pharmaceutical Industry (ABPI) represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK. ABPI Cymru Wales was established in 2003 in response to the evolving distinctiveness of the health agenda in Wales. It supports the work of the ABPI Cymru Wales Industry Group (WIG), a collaboration of ABPI members with a declared interest in Wales.
ABPI Cymru Wales and its member companies work in partnership with the National Assembly for Wales, Welsh Assembly Government, NHS Wales, Patient Advocacy Groups and other key stakeholders, to help address the health needs of the people of Wales. We share a common commitment to improve the lives of the people of Wales and we work alongside healthcare professionals and patients under the strict governance arrangements of the ABPI Code of Practice. This ensures that medicines promotion and joint working with the NHS are conducted in an open, responsible and ethical way.
ABPI Cymru Wales is committed to working with our partners to support a common understanding and a shared value for new and innovative medicines.